In Brief
A common sequence variant that perturbs long-range enhancer interactions mediates risk for different vascular diseases.
INTRODUCTION
Coronary artery disease (CAD) remains the leading cause of morbidity and mortality worldwide and is heritable. Genomewide association studies (GWASs) have mapped >65 genomic loci for CAD, with most residing in non-coding sequence (CARDIoGRAMplusC4D Consortium et al., 2013; Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators et al., 2016; Nikpay et al., 2015; Webb et al., 2017) . At many of these loci, the causal DNA sequence variant, gene, and mechanism remain undetermined. The diversity of cell types potentially involved in CAD pathogenesis (endothelial cells, smooth muscle cells, monocytes, and cells of the adaptive immune system) complicates functional determination of the underlying causal mechanisms. As a result, successful translation of SNP associations into causal genes and biologic pathways has been confined to a small subset of GWAS loci in CAD (Bauer et al., 2015; Musunuru et al., 2010; Nurnberg et al., 2015) .
The identification of causal genes for CAD has relied on connecting a variant with genetic expression differences, which is now broadly available through the GTEx consortium (GTEx Consortium, 2013) . Though there is mounting evidence that many GWAS variants regulate transcription (Maurano et al., 2012; Roadmap Epigenomics Consortium et al., 2015; Schaub et al., 2012) , these data are not sufficient to identify the causal gene(s) at a locus given the large number of cisexpression quantitative trait locus (eQTL) relationships that exist for many variants. Though disease-associated loci are often named by the closest gene to the variant, or the gene with the strongest eQTL, neither can identify a causal gene with certainty.
Here we focus on a genomic locus associated with CAD and four other vascular disorders. Common DNA sequence variants at 6p24 have shown genome-wide significant association with early-onset myocardial infarction (Myocardial Infarction Genetics Consortium et al., 2009) , CAD (CARDIoGRAMplusC4D Consortium et al., 2013; Nikpay et al., 2015) , coronary artery calcification (O'Donnell et al., 2011) , migraine headache (Anttila et al., 2013) , cervical artery dissection (Debette et al., 2015) , fibromuscular dysplasia (Kiando et al., 2016) , and hypertension (Surendran et al., 2016) , a constellation of diseases suggesting an effect on vascular function. The associated variants at 6p24 lie within the third intron of the gene encoding phosphatase and actin regulatory protein 1 (PHACTR1), nominating PHACTR1 as the effector gene given its physical proximity. In support of this hypothesis, an association exists between risk genotype and PHACTR1 expression in arterial samples (Aguet et al., 2016; Beaudoin et al., 2015) , and PHACTR1 function is linked with atherosclerosis-relevant phenotypes, such as angiogenesis (Jarray et al., 2011) , extracellular matrix protein production (Jarray et al., 2015) , and inflammation (Reschen et al., 2016) in vitro. Despite these data, the causal gene at the 6p24 locus remains uncertain. Furthermore, the mechanism that links the causal variant to gene expression at this locus is not known. To dissect how the 6p24 locus affects vascular disease risk, we utilized genetic and epigenomic approaches to identify the causal variant in the locus, the gene(s) regulated by the variant, and the mechanism by which the DNA variant affects the gene.
RESULTS

Fine Mapping Prioritizes a Causal Variant at 6p24
CAD GWASs have identified association between a group of variants in linkage disequilibrium at 6p24 and several diseases. Sequencing at the locus in a French-Canadian cohort has prioritized an intronic variant in this region (Beaudoin et al., 2015) . We conducted genetic fine mapping using the data from the CARDIOGRAMplusC4D Consortium (194, 427 individuals) , and we imputed SNP associations from the 1000 Genomes Project ( Figure 1A ). Imputation-based fine mapping combines summary level data from the large-scale CARDIOGRAMplusC4D analysis with linkage disequilibrium estimation from a reference set of similar ancestry. This approach can refine the association signal at a previously identified locus (Yang et al., 2012) . The strongest association was for a single variant, rs9349379, with an association of 1.81 3 10 À42 (odds ratio [OR] = 1.14), far exceeding the association signal for the next most highly associated SNP, rs78145402 (OR = 1.08, 4.69 3 10 À17 ).
We next conducted a conditional analysis at the 6p24 locus to determine if there exists an association independent of the sentinel SNP. This conditional analysis, after adjusting for rs9349379, showed no evidence of a second independent CAD/myocardial infarction (MI) association at this locus (Figure S1) . The Probabilistic Identification of Causal SNPs (PICS) algorithm (Farh et al., 2015) also identifies rs9349379 as the causal SNP, given the haplotype structure at the locus, with greater than 99% probability (Table S1 ). Thus, statistical evidence prioritizes rs9349379 as a likely causal SNP for the multiple vascular disease associations at this locus.
Phenome-wide Analysis Confirms Vascular-Specific Effect of Causal 6p24 SNP Phenome-wide association studies (PheWASs) enable unbiased assessment of the relationship between a given variant and a broad range of human disease phenotypes. This approach is particularly useful for a variant, such as rs9349379, with known impact on several diseases. We conducted a PheWAS for this variant in the UK Biobank using individual-level data from No variants in the locus are in significant LD with rs9349379 (r 2 >0.5).
(B) Multiple disease associations of rs9349379 minor allele (G) with vascular disorders. The minor allele (G) is associated with increased risk of CAD and coronary calcification. The minor allele is alternatively associated with reduced risk of cervical dissection, migraine headache, fibromuscular dysplasia, and hypertension. CAD and migraine headache associations are confirmed in UK Biobank data.
112,338 individuals of European ancestry. The UK Biobank PheWAS confirmed the previously published associations for CAD and migraine headache ( Figure 1B ; CAD p = 1.16 3 10
À11
; migraine p = 0.000717). The pattern of association is striking as the minor allele at rs9349379 (G, 36% frequency) leads to increased risk for CAD and coronary calcification but decreased risk for four conditions (migraine headache, cervical artery dissection, fibromuscular dysplasia, and hypertension). Analysis for association between rs9349379 and cardiovascular risk factors confirmed the previously reported association with systolic blood pressure, but no relationship with lipid concentrations, weight, diabetes, or other related measures ( Figure S1B , data obtained from analysis of multiple studies listed in Table S3 ). There was no significant association of rs9349379 with any other diseases in the UK Biobank PheWAS ( Figure S1C ).
Given the association of rs9349379 with vascular phenotypes, we next determined its relationship with relevant sub-phenotypes. First, in the UK Biobank, we investigated whether the rs9349379 genotype was associated with a measure of arterial stiffness. Arterial stiffness index was measured in the upper extremity using a digital sensor attached to the participant's digit. In 38,817 participants of European ancestry, the G allele at rs9349379 was associated with decreased arterial stiffness index, with b = À0.077 (95% confidence interval [CI]: À0.034, À0.119), p = 0.0004. Second, we used data from a meta-analysis conducted by the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium to quantify the effect of rs9349379 on endothelium-dependent flow-mediated vasodilation (FMD). Flow-mediated vasodilation is a standardized assay of endothelial cell function evoked following brief occlusion of the brachial artery (Corretti et al., 2002) . Brachial artery flow-mediated vasodilation was measured in 16,662 participants using ultrasound-guided measurement of brachial artery diameter before and immediately following brief occlusion of the vessel by suprasystolic inflation of a blood pressure cuff. The G allele at rs9349379 was associated with decreased flow-mediated vasodilation (b = À0.1209 [95% CI: À0.5535, À0.6188], p = 0.004). Flow-mediated vasodilation is provoked by shear stress on the endothelium and subsequent dilation in response to vasoactive peptides generated by endothelial cells (Sorensen et al., 1995) . In aggregate, these genetic data suggest a role for rs9349379 in human endothelial cell function, and our subsequent experiments prioritized the use of endothelial cells to characterize underlying mechanisms.
A Vascular-Specific Regulatory Region at rs9349379 Non-coding variants often affect gene expression by altering the function of enhancer elements, which can control celltype-specific gene expression programs. Prior studies have used overlap with enhancer elements to prioritize a cell or tissue type for functional analysis of GWAS loci (Farh et al., 2015; Ren and Yue, 2015) . In pursuit of a tissue or cell in which rs9349379 has relevant regulatory function, we examined the occupancy of a histone mark associated with enhancer activity (H3K27Ac) at the locus in all tissues and cell types annotated in the Encyclopedia of DNA Elements (ENCODE) project (ENCODE Project Consortium, 2012). However, there was no detectable H3K27Ac signal at this locus in these datasets (Figure 2A) . Notably, vascular tissues were not included in the ENCODE catalog of chromatin states. The newly released ENCODE phase 3 data, however, includes four aortic artery samples. In these aortic samples, a strong enhancer signal overlies rs9349379 ( Figure 2B ), spanning 1 kb. Of these aorta samples, two were homozygous major (A/A) at rs9349379, one heterozygous (A/G), and one homozygous minor (G/G). All four demonstrate robust H3K27 acetylation at rs9349379 ( Figure S2 ). These data suggest a gene regulatory function exists at this locus in vascular tissue.
Targeted Deletion at the 6p24 Regulatory Element Increases EDN1 Expression in Vascular Cells
To determine the target gene of the regulatory element at rs9349379, we performed genome-editing experiments in pluripotent stem cells, and we differentiated these cells into two vascular cell types: endothelial cells (ECs) and vascular smooth muscle cells (VSMCs). First, we deleted an 88-bp region at rs9349379 in an induced pluripotent stem cell (iPSC) line using CRISPR/Cas9 with flanking single-guide RNAs (sgRNAs) (Figure 3A) . High-efficiency sgRNAs were designed, constructed, and tested for nuclease activity as previously described (Peters et al., 2013) . The highest efficiency sgRNAs were nucleofected into iPSCs, and three clones with a bi-allelic 88-bp deletion (D88) were generated from a total of 384 screened clones (Figure S3A ). These clones, along with three unedited wild-type clones that had also been exposed to the CRISPR/Cas9 complex, were expanded and differentiated into ECs and VSMCs as previously described (Patsch et al., 2015) . In both iPSCderived ECs and VSMCs, loss of the 88 bp flanking rs9349379 resulted in higher expression of the endothelin-1 (EDN1) gene compared with wild-type lines ( Figure 3B ).
Expression of five other genes in the 1-Mb region surrounding rs9349379, including PHACTR1, did not differ significantly for either cell type. There was no differential gene expression between wild-type (WT) and D88 iPSCs differentiated to a nonvascular cell type, neural crest progenitor cells ( Figure S3B ). Though EDN1 expression was differentially regulated in both ECs and VSMCs, there was a 50-fold higher expression in ECs ( Figure S3C ). We therefore focused further experiments to characterize cis regulation by rs9349379 in ECs.
To determine if the cis regulation of EDN1 by the 6p24 regulatory element was present in a different pluripotent cell line, we edited an embryonic stem cell (ESC) line as well. ESC-derived ECs confirmed the regulatory effect, and D88 ESC-ECs demonstrated higher expression compared with WT ESC-ECs (Figure 3C ; p = 0.0004). In ECs, EDN1 is dynamically upregulated in response to inflammatory stimuli (Yoshizumi et al., 1990) . We incubated the WT and D88 iPSC-derived ECs with interleukin-1a (IL-1a), a potent inflammatory stimulus that induces EDN1 expression. Stimulation with IL-1a increased EDN1 expression both in WT and D88 ECs at the mRNA ( Figure 3D ; p = 0.005) and protein levels ( Figure 3E ; p = 0.0004).
These data demonstrate that deletion of a small region of apparent regulatory DNA at rs9349379 results in increased EDN1 expression and endothelin-1 (ET-1) protein production in ECs and to a lesser extent in VSMCs.
CRISPR/Cas9-Generated Allelic Series at rs9349379 Validates the Regulatory Effect on EDN1 Expression To determine if the effect on EDN1 gene expression is specifically mediated by a genotype at rs9349379, we generated isogenic stem cell lines that were either homozygous major (A/A) or homozygous minor (G/G). Homologous recombination (HR) with CRISPR/Cas9 genome editing proved to be inefficient, due to a lack of high-efficiency sgRNAs in this AT-rich region of the genome and an inability to inactivate the sgRNA once HR successfully occurred. We tested several approaches to improve the efficiency of HR, including use of multiple sgRNAs in the locus, SCR7 inhibitors (Maruyama et al., 2015) , and Cpf1 nucleases (Zetsche et al., 2015) ; however, in screening over 2,500 colonies, we were only able to recover two clones with successful HR without other insertions or deletions (indels) (Figures S4A and  S4B ). The only successful approach required two rounds of genome editing: first to generate a cell line with protospacer adjacent motif (PAM) sites at the SNP with HR and second to generate the allelic series (Paquet et al., 2016) (Figure 4A ). Using this approach, 15% of clones had the appropriate genotype with no additional edits beyond the 1-bp change ( Figure S4C ). Three clones from each genotype (A/A and G/G) were selected for expansion and differentiation to ESC-ECs. RNA sequencing (RNA-seq) was conducted on the six samples to identify cisand trans-regulatory effects of rs9349379. A total of 173,259 transcripts were analyzed. We found 279 differentially expressed (false discovery rate [FDR] < 0.05) transcripts, with clustering of samples according to rs9349379 genotype as expected (Figure 4B) . The majority of these differentially expressed transcripts had log2 fold changes <1.5 (243/279, 87%; Figure S4D ). Gene set enrichment analysis of the differentially expressed genes showed strong enrichment for blood vessel development (FDR = 1.64 3 10 À10 ), vasculature development (FDR = 2.98 3 10 À10 ), and blood vessel morphogenesis (FDR = 2.21 3 10 À9 ). EDN1, a gene over 600 kb distal to rs9349379, was the only differentially regulated gene within 2 Mb of rs9349379 (Figure 4C) . The differentially regulated genes included several mediators of vascular wall integrity and structure, such as COL4A1, COL3A1, and FN1 ( Figure S4E ), which may be downstream effects of increased EDN1 expression in the G/G ESC-ECs (Amiri et al., 2004; Shi-Wen et al., 2001 ). RNA-seq was also conducted in six WT and six D88 cells, and, of the 173,259 analyzed transcripts, there were 423 differentially regulated genes ( Figure S4F ). There was significant overlap in the gene set enrichment analysis represented by these differentially regulated genes and those from RNA-seq of the A/A and G/G ESC-ECs. The top pathways were also blood vessel development (FDR = 2.6 3 10 À7 ) and blood vessel morphogenesis (FDR = 2.6 3 10 À7 ). In RNA-seq from both the deletion and allelic series ECs, the regulatory effects of rs9349379 localized to vascular development pathways, and they may be explained by the cis-regulatory effect on EDN1 expression. The qPCR confirmed the differential gene expression seen by RNA-seq, and it demonstrated a cis-regulatory effect of genotype at rs9349379 on EDN1 expression, with the minor allele driving increased EDN1 expression ( Figure 4D ; p = 7.59 3 10 À7 ). There was a significant difference in TBC1D7 expression by qPCR (p = 1.75 3 10 À5 ); however, this was not seen in the RNA-seq quantification from separately differentiated cells or the D88 deletions. The homozygous minor ESC-ECs also produced more ET-1 protein in the cell-free supernatants at 24 hr in the presence or absence of IL-1a stimulation ( Figure 4E ; unstimulated p = 2.12 3 10 À5 and IL-1a stimulated p = 0.0006). To determine the regulatory effect in another vascular cell type, the A/A and G/G ESC lines were differentiated into VSMCs. EDN1 was the only differentially expressed transcript in the 6p24 locus ( Figure 4F ; p = 0.012) in VSMCs; however, the level of EDN1 expression was 50-fold lower in VSMCs than in ECs.
Very Low Contact between EDN1 and rs9349379 by Three-Dimensional Chromatin Structure One possible mechanism by which the distal regulatory element at rs9349379 affects EDN1 expression is direct contact with the EDN1 promoter site. Chromatin loops regulate gene expression by positioning distal enhancers in proximity to target genes (Deng et al., 2012; Dowen et al., 2014). To measure the threedimensional (3D) chromatin topology in this region, circularized chromosome conformation capture sequencing (4C-seq) assays were performed in human coronary artery ECs. 4C-seq revealed a very low contact probability and no evidence for a focal loop between rs9349379 and the EDN1 promoter ( Figure 5A ). The EDN1 promoter contacts multiple sites extending up to 500 kb in both the 3 0 and 5 0 directions. 4C-seq from the rs9349379 site demonstrated a smaller contact region that extended from chr6:12,690,000-13,350,000. There was a possible area of overlap intergenic to EDN1 and PHACTR1 ( Figure 5A ). Notably, this region featured high levels of H3K27Ac signal in ECs, consistent with a super enhancer ( Figure (E) Increased Big ET-1 expression before and after IL-1a stimulation in homozygous minor (G/G) ESC-derived ECs (*p = 2.12 3 10 À5 and **p = 0.0006).
(F) Homozygous minor ESC-derived VSMCs demonstrate higher expression of EDN1 (*p = 0.012), while no other 6p24 locus genes show differential expression. All data represent mean ± SEM of three independently differentiated clones of each genotype.
regions of cis-regulatory DNA that span up to 12.5 kb, amass large quantities of coactivator proteins, and control cell-typespecific gene expression programs (Parker et al., 2013; Whyte et al., 2013) . The common contact region contains four distinct peaks of H3K27Ac signal. Reporter assays with each of these four sites cloned into an SV40-driven luciferase plasmid demonstrated that each cis element possessed strong enhancer activity in 293T cells (2-to 12-fold luciferase induction) compared with SV40-promoter sequence alone ( Figure 5C ). The same chromatin structure was seen in 4C-seq from aortic ECs, iPSCderived ECs, aortic VSMCs, and primary human monocytes ( Figure S5 ). The significance of these long-range chromatin loops in the regulation of EDN1 merits further study, but they suggest that the regulatory effect of rs9349379 on EDN1 is not through traditional enhancer-promoter interactions.
Minor Allele G at rs9349379 Increases Plasma Levels of Big ET-1 in Healthy Subjects
We next tested the effect of genotype at rs9349379 on plasma levels of Big ET-1. The pro-peptide Big ET-1 is the larger precursor product of EDN1 transcription, and it is secreted and cleaved into the active ET-1 peptide. The 21-amino acid active ET-1 peptide is quickly degraded in vivo; however, the Big ET-1 pro-peptide is more stable and, therefore, measured more reliably in human plasma samples (Woods et al., 1999) . Given the effect on EDN1 expression in genome-edited ECs, we postulated that Big ET-1 levels would be higher in individuals with the minor allele at rs9349379. We limited our analysis to healthy individuals, given previous reports of alterations in ET-1 levels in patients with pulmonary hypertension and heart failure. From the Partners Biobank cohort, patients with a Charlson Comorbidity Score of 0 and no anti-hypertensive medication use were selected for analysis. A total of 99 plasma samples were obtained, with 33 samples of each genotype at rs9349379 (A/A, A/G, G/G). We found a significant association between G genotype at rs9349379 and higher Big ET-1 levels using an additive model of regression ( Figure 6 ; p = 0.00136). There was no significant effect of sex on ET-1 expression ( Figure S6 ; p = 0.26). This analysis provides further support in human samples of the association between rs93493979 and the vasoactive ET-1 peptide.
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Figure 5. Very Low Contact between EDN1 Promoter and rs9349379 by 3D Chromatin Structure (A) 4C-seq in human coronary artery ECs demonstrates 3D chromatin loops from the EDN1 promoter viewpoint (red) and rs9349379 SNP viewpoint (blue). The EDN1 promoter contacts multiple sites extending up to 500 kb in both the 3 0 and 5 0 directions. 4C-seq from the rs9349379 viewpoint demonstrates a smaller contact region that extends from chr6:12,690,000 to 13,350,000. There is a common contact area intergenic to EDN1 and PHACTR1 (*). (B) Super enhancer at chr6:12,490,000-12,590,000 seen in H3K27Ac ChIP-seq in human umbilical vein endothelial cell (HUVEC), iPSC-derived EC, and embryonic-derived EC. The super enhancer is within the same transcriptionally associated domain as EDN1, and it also includes the common contact sites of the EDN1 promoter and rs9349379 regulatory element. HUVEC, iPSC-EC-B, and embryonic-EC were generated from publicly available data.
(C) Demonstration of strong enhancer activity for each of the four discrete regions that comprise the super enhancer. The 2-kb segments were tested in a luciferase expression assay and compared with empty vector (EV); each region had a 2-to 12-fold induction of luciferase signal.
DISCUSSION A New Mechanism of Regulation for Five Vascular Diseases
The 6p24 locus is linked to five vascular diseases through common variant association studies. Here we identify the causal variant and gene in vascular tissue using the integration of genetic fine mapping, epigenomic profiling, and CRISPR/Cas9 genome editing. We show the allele-specific regulation of EDN1 expression in pluripotent stem cell lines with CRISPR/ Cas9-mediated bi-allelic deletions, an isogenic allelic series generated through two-step HR, and direct measurement of ET-1 protein in human plasma samples. ET-1, the protein product of the EDN1 gene, is a 21-amino acid peptide originally discovered in the supernatant of cultured aortic ECs. It functions as the most potent, longest-lasting vasoconstrictor in humans, and it has unrelated roles in neural crest development and regulation of salt balance in the renal collecting ducts (Pollock, 2010) . ET-1 is primarily produced by ECs, though it is secreted abluminally toward underlying smooth muscle cells (Wagner et al., 1992) . It acts in a paracrine fashion to promote atherosclerotic plaque development through VSMC-mediated vasomotor constriction, remodeling, and proliferation (Amiri et al., 2004; Li et al., 1994; Schiffrin, 2005) . Of note, DNA variants proximal to the promoter of EDNRA, encoding Endothelin A (ET A ) receptor (one of two receptors for ET-1), show genome-wide significant association with CAD ( Figure S7 ).
Our data indicate that increased endothelial production of ET-1 and subsequent binding to the ET A receptor promotes atherosclerosis. This hypothesis has been experimentally validated in earlier studies. Endothelial-specific overexpression of Edn1 in Apoe À/À mice led to increased atherosclerosis (Li et al., 2013) . Selective ET A antagonists have been shown to retard the development of atherosclerosis in western-type diet-fed Apoe À/À mice and hamsters (Barton et al., 1998; Kowala et al., 1995) . In addition to CAD, there are four additional vascular disease associations at the 6p24 locus. The G allele at rs9349379 is associated with decreased risk for migraine headache, cervical artery dissection, and fibromuscular dysplasia-three diseases that co-occur epidemiologically (Olin et al., 2014; Pezzini et al., 2005; Rubinstein et al., 2005) . Migraine headache is associated with intracranial and meningeal vasodilation (Asghar et al., 2011; Bolay et al., 2002) . Our data are consistent with this physiology, as the G allele at rs9349379 results in higher EDN1 expression, increased ET-1 binding to the ET A receptor on VSMCs, vasoconstriction, and, therefore, reduced risk of migraine headache. At present, little is known about the pathophysiology of cervical artery dissection or fibromuscular dysplasia, and the precise relationship of either disease with vascular tone is uncertain. In addition to vasoconstriction, other effects of ET-1 on VSMCs include proliferation (Hirata et al., 1989) , extracellular matrix (ECM) production (Amiri et al., 2004; Shi-Wen et al., 2001) , and fibrosis (Xu et al., 2004) . The genetic data suggest the shared pathophysiology of migraine, dissection, and fibromuscular dysplasia may occur through one or more of these downstream effects of ET-1, though this requires further investigation.
Finally, the association of the G allele with lower systolic blood pressure (Surendran et al., 2016) may be explained by the action of ET-1 on the second endothelin receptor, ET B . In contrast to the coronary arteries where ET A receptors predominate, ET B receptors are more abundant in the large systemic arteries (Bacon et al., 1996) . ET-1 binds to ET B receptors on ECs in large vessels, triggering endothelium-dependent vasodilation through the production of nitric oxide, prostacyclins, and renal naturiesis (Hirata et al., 1993) . The ET A :ET B ratio explains why ET-1 acts as a vasoconstrictor in some vascular beds and a vasodilator systemically. Of note, mice with deletions of one copy of Edn1 (Edn1 +/À ) display hypertension, a result consistent with our working model (Kurihara et al., 1994) . Additionally, ET-1 can reduce blood pressure by promoting diuresis and natriuresis via ET B receptors in the renal collecting system (Ge et al., 2005; Kohan et al., 2011) . In Figure 7 , we summarize the multiple physiologic effects of ET-1 on the vasculature, and we propose a hypothetical model for the relationship between the G allele at rs9349379 and risk for five vascular diseases.
One challenge with the functional assessment of common, non-coding variation is the modest effect each variant has on gene expression. In this study, the cis-regulatory effect of the causal variant is a 20% increase in EDN1 expression in the genome-edited ECs homozygous for the G allele. These data are consistent with several examples of non-coding, common variation with this modest level of transcriptional regulation (Bauer et al., 2013; Musunuru et al., 2010; Smemo et al., 2014; Sur et al., 2012; Tewhey et al., 2016) . In each case, the effect of a common variant on gene expression is modest; however, stronger perturbation of the causal gene by either genetic (e.g., gene deletion) or pharmacologic means can lead to larger effects.
A second challenge in the study of non-coding variation is understanding the mechanism of distal regulation. Though, in the majority of cases, variants regulate the most proximal gene (Shin et al., 2014) , long-range chromatin interactions can mediate distal regulatory effects. Newly available methods to characterize the regulatory elements and 3D architecture in GWAS loci allow a broader assessment of relevant genes. Here we demonstrate the regulation of a gene 600 kb from the causal variant. The mechanism of the distal cis-regulatory effect at 6q24 does not appear to be through canonical enhancer-promoter contact. Instead, the data point to a common contact site approximately 300 kb from both the EDN1 promoter and rs9349379 regulatory element. This common contact site also contains a series of strong enhancers, as demonstrated by H3K27Ac signal. Recent studies support the notion that enhancer regulation of gene expression may include mechanisms that do not involve direct contact with a promoter. Enhancers can affect transcription through interactions with insulators (Flavahan et al., 2016) , promoters for distal genes (Fukaya et al., 2016) , and other enhancers (Vockley et al., 2016) . The EDN1 locus may represent another example of such distal regulation, but further work is necessary to establish the mechanism by which the common contact site mediates gene expression.
In summary, we provide several lines of evidence that a common DNA variant associated with five vascular diseases regulates a gene, EDN1, located over 600 kb upstream in genomic distance. Selective modulation of endothelin-1 function in the appropriate vascular bed may prove useful in the treatment of diseases, such as CAD, migraine headache, cervical artery dissection, fibromuscular dysplasia, and hypertension.
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Rajat Gupta (rgupta@broadinstitute.org).
MTAs are required for human pluripotent stem cell lines. MTAs can be obtained through the Harvard Stem Cell Institute iPSC Core.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Lines Pluripotent stem cell lines All pluripotent stem cell lines are grown in mTeSR1 media, and supplemented with Y-27632 at passaging. Standard culture conditions (37 C, 5% CO 2 ). Human embryonic stem cell lines HUES 9 and HUES 66 and induced pluripotent stem cell line 1016 were obtained from the Harvard Stem Cell Institute after completion of a material transfer agreement. Cells were authenticated and karyotyped at the time of purchase. DiPS 1016SevA iPSC cells: Reprogrammed from Fibroblasts by Sendai Virus method. Healthy male donor. HUES 9: Hematopoetic stem cell, Female donor HUES66: Hematopoetic stem cell, Female donor.
Primary Cell Cultures
All primary human endothelial cell lines were purchased from Lifeline Cell Technology, and grown in VascuLife EC Growth Media using standard culture conditions (37 C, 5% CO 2 ). Human coronary artery endothelial cells were from a deceased female donor, and human aortic endothelial cells were from a deceased male donor. Primary human monocytes Primary human CD14+ monocytes were isolated from peripheral blood (Leukopacs, MGH blood bank) by positive selection using CD14 MicroBeads (Miltenyi) according to the manufacturer's instructions. Three samples were obtained, representing 2 male and 1 female donors. Human subjects De-identified plasma samples were obtained from the Partners Healthcare Biobank. All participants are consented upon enrollment in the Biobank, and separate IRB approval is not required for these de-identified samples. Samples were selected for participant age 20-49 years, no current smoking, no hypertension diagnosis or anti-hypertensive use, no other medical diagnoses (defined by Charlson comorbidity index of 1), caucasian race. 99 plasma samples were obtained, 33 of each genotype at rs9349379 (A/A, A/G, G/G). 72 samples were from female donors, 28 from male donors with an even distribution of male and female samples in each genotype group.
METHOD DETAILS Association analyses in population cohorts
Phenome-wide association analysis in UK Biobank We conducted a PheWAS for this variant in the UK Biobank (http://www.ukbiobank.ac.uk) using individual-level data from 112,338 individuals of European ancestry. Presence of 36 different diseases at baseline were defined by verbal interview with a trained nurse (definitions are provided in Table S2 ). Logistic regression, adjusting for age, sex, ten principal components of ancestry and a dummy variable for the array type used in genotyping, was used to test for the presence of association between rs9349379 and each of the 36 different diseases. A Bonferroni-adjusted p value of 0.0014 (0.05/36) was used as the threshold for statistical significance.
Arterial Stiffness Index Analysis
In UK Biobank, 38,795 individuals of European ancestry with available genotype data and arterial stiffness index (ASI) measurement were analyzed. ASI was measured by the PulseTrace PCA2 device (CareFusion, San Diego, USA). The PulseTrace PCA2 device is a pulse-wave, infra-red sensor that is placed on the participant's digit. ASI is defined as the participant's height divided by the time from when an initial pulse wave reaches the digital tip to when the same pulse wave travels through the aorta and lower extremity arterial system, and reflects back to the digital sensor. As such, larger ASI values reflect stiffer large arterial circulation. Extreme outliers (5 > standard deviations from the mean) were excluded. Association analysis in UK Biobank consisted of linear regression, ASI as the dependent variable, SNPs coded in an additive model, and covariates of age, sex, array type, and principal components utilizing R and PLINK (http://zzz.bwh.harvard.edu/plink/) statistical software programs. 
Flow-mediated vasodilation Analysis
ENCODE analysis
Histone marks in the 6p24 locus were queried from the Roadmap epigenomics database. Analysis was conducted across all available tissue types in ENCODE phase one and two data. Newly released ENCODE phase 3 includes four aorta samples.
Re-analyzed, publicly available data: ChIP-Seq in aortic tissue Histone modification ChIP-seq data can be accessed via the ENCODE project data portal.
Separate links for the 4 Aortic tissue samples are:
https://www.encodeproject.org/experiments/ENCSR015GFK/ https://www.encodeproject.org/experiments/ENCSR318HUC/ https://www.encodeproject.org/experiments/ENCSR069UMW/ https://www.encodeproject.org/experiments/ENCSR982QIF/ Analysis of histone marks was conducted using coordinates chr6:12,850,000-12,960,000. Rpm/bp plots were generated for H3K27Ac, H3K4me3, H3K36me3, H3K27me3, H3K9me3 using bamplot software (Lin Lab: https://github.com/linlabbcm/ bamplot).
4C-Sequencing Analysis
4C-seq was performed as previously described (van de Werken et al., 2012) using DpnII for the first digestion, and Csp6I for the second digestion. In brief, cells were crosslinked in 2% formaldehyde-PBS-10%FCS for 10 min at room temperature. After crosslinking, cells were incubated in lysis buffer while tumbling for an hour at 4 C. Cells were pelleted, washed, and resuspended in DpnII buffer. SDS was added to a concentration of 0.3% for an hour incubation in a thermomixer at 37 C and 400 rpm. Triton X-100 was then added to a concentration of 2.6% and cells were incubated for another hour. 200 units of DpnII enzyme were added for a 4 hr incubation in a thermomixer at 37 C and 900 rpm; another 200 units of DpnII were added for overnight incubation. Cells were then incubated for 20 min at 65 C to heat inactivate DpnII, suspended with ligation buffer and 50 units of ligase to a volume of 7 mL and then incubated overnight at 16 C. 300 mg Proteinase K was added for overnight incubation at 65 C. DNA was purified using NucleoMag P-Beads and taken up in restriction buffer with 50 units of Csp6I and incubated for 4 hr in a thermomixer at 37 C and 900 rpm, followed by heat inactivation of the enzyme (65 for 25 min). Sample was diluted with ligation buffer to a DNA concentration of < 5 ng/ml. 100 units of ligase was then added for overnight incubation at 16 C. DNA was purified using NucleoMag P-Beads and taken up in 5mM Tris pH7.5.
The 4C-seq PCRs were performed using rs9349379 (reading primer TTATCCTTATTCATTTGATC and non-reading primer CTTTGCCCTTAGAAAGGTTT) and the EDN1 promoter (reading primer GGTTTGGACAGACTCAGATC and non-reading primer TGTCTAACCTGAAAAATGGG) as viewpoints. Primers were extended with dangling Illumina adaptor sequences. Viewpoint fragments were selected based on fragment size (DpnII-DpnII > 400 bp), fragment-end size (DpnII-Csp6I > 200 bp) and opportunities for specific primer design (Primer 3) close to (< 20 bp away from) the DpnII primary restriction site (van de Werken et al., 2012) .
Sequencing reads were demultiplexed and trimmed of the primer sequence using demultiplex.py from FourCSeq package (Klein et al., 2015) , aligned using bowtie2 (v2.2.5) with standard parameters and quality filter set to 1 (-q 1) and processed as described (van de Werken et al., 2012) . In short, reads are mapped to a restricted human reference genome (hg19), consisting of sequences directly flanking the 4C primary restriction enzyme site (DpnII), called 4C frag-ends. Non-unique frag-ends are discarded in subsequent analysis. After mapping, the highest covered frag-end was removed from the dataset in the normalization process and data are read-depth normalized to 1 million aligned intrachromosomal reads. 4C-Seq coverage profiles are calculated as ''running means,'' i.e., coverage averages of 21 consecutive 4C frag-ends.
Luciferase expression constructs
To functionally validate the common contact region, 2kB segments surrounding each H3K27Ac peak were cloned into the multiple cloning site of the pGL4-SV40 vector (Promega) using standard restriction-enzyme cloning or Gibson assembly. All constructs were verified by Sanger sequencing of plasmids.
Luciferase reporter assays 293T cells were routinely cultured in DMEM/10% FBS until ready for transfection. Bovine aortic endothelial cells (Cell Applications) were routinely cultured in DMEM/10% FBS until ready for transfection. 10,000 293T cells or 20,000 bovine aortic endothelial cells were plated in each well of a 96-well plate and transfected with 100ng of total plasmid DNA. Luciferase plasmids were co-transfected with renilla plasmids as a transfection control in either a 1:1 ratio (293T cells) or 1:5 ratio (bovine aortic endothelial cells). 293T cells were transfected using FuGene 6 (Promega) and bovine aortic endothelial cells were transfected using Viafect (Promega). Twentyfour hours after transfection, firefly and renilla luciferase activities were measured using the Dual-Luciferase Reporter Assay System (Promega) according to the manufacturer's protocol.
CRISPR/Cas9 guide selection and cloning Using computational algorithms with prioritization for on-target efficiency and reduced off-target effects (available online: CRISPR Design tool (crispr.mit.edu), we identified Streptococcus pyogenes Cas9 (SpCas9) guide RNAs that bind near rs9349379. We selected all possible sgRNA sequences within 100bp of the target SNP (rs9349379). Annealed oligomers inclusive of guide RNA sequences were subcloned into the PX459v2 plasmid, which contains expression cassettes for the guide RNA, a human codon-optimized Cas9, a puromycin resistance gene. Plasmids were transformed into chemically competent E. coli (Sbtl3, Thermofisher), and grown; plasmid DNA was extracted and purified.
Surveyor assays 293T cells were routinely grown in DMEM/10% FBS until ready for transfection. 40,000 293T cells were transfected with 1ug of each CRISPR construct. Genomic DNA was harvested and a 280 base pair region flanking rs9349379 was PCR-amplified and purified. Purified product was heteroduplexed, digested with Surveyor nuclease, and products run on a 2% agarose gel. Cleavage patterns were qualitatively analyzed to determine constructs cutting efficiency to guide further experiments.
Genome editing in human stem cells Human embryonic and induced pluripotent stem cell lines were genotyped at rs9349379 via Sanger sequencing. Cells were routinely grown in mTeSR1 media, with Y-27632 at passaging, until ready for transfection. 800,000 stem cells were nucleofected with 5ug of CRISPR plasmid constructs and 7.5ug of a 200bp single single-stranded oligodeoxynucleotide donor template (ssODN). Following transfection, stem cells underwent 48 hr of puromycin selection at 1ug/mL (Hues 9 and 1016) or 0.5ug/mL (Hues 66). Following 5 days of cell growth, individual colonies were isolated, genomic DNA was extracted and PCR amplified, and screened for desired mutations. To account for off-target effects of the Cas9 nuclease, 3 wild-type and 3 clones with each desired mutations were expanded.
To delete 88 base pairs of noncoding sequence around rs9349379, we utilized a dual-guide RNA strategy using two Cas9-guide RNA constructs with 80bp of spacing between guide RNAs. These deletions were generated in both a homozygous major induced pluripotent stem cell line (1016) and a homozygous minor embryonic stem cell line (Hues 9). Genomic deletions were screened for with agarose gel electrophoresis of PCR amplicons and confirmed with Sanger sequencing of PCR amplicons. In each cell line, 3 wild-type and 3 biallelic 88 base pair deletions were selected for further study.
Due to the nature of non-coding sequence, minimal SpCas9 protospacer adjacent motifs (PAMs), which are required for Cas9-guide RNA recognition of target sequence, were available for genome editing at rs9349379. Hence, we pursued two rounds of genome editing to introduce a single base pair variant. The first round of editing replaced rs9349379 and the two adjacent base pairs with guanine nucleotides. Individual colonies with replaced nucleotides were expanded for the second round of genome editing, utilizing the new guanine nucleotides as PAMs. To restore wild-type sequence and insert a single variant at rs9349379, ssODNs containing either the major or minor allele (wild-type elsewhere) were used as repair templates. 3 homozygous major and 3 homozygous minor clones were selected for further study. Figure S1 . Related to Figure 1 1A) Conditional analysis at the 6p24 locus shows no secondary association for coronary artery disease after signal associated with causal SNP, rs9349379, is removed. No SNP in the locus shows genome-wide significant association in the conditional analysis. 1B) No association between rs9349379 and traditional cardiovascular risk factors measured in multiple GWAS for these traits (summarized in Table S3 ). 1C: No association between rs9349379 and other diseases in UK Biobank. 
